C
CURIS INC
NASDAQ: CRIS (Curis, Inc.)
Kemas kini terakhir: 14 jam lalu0.714
0.05 (8.02%)
| Penutupan Terdahulu | 0.661 |
| Jumlah Dagangan | 32,240,483 |
| Harga / Jualan (P/S) | 0.160 |
| Harga / Buku (P/B) | 0.250 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -426.77% |
| EPS Cair (TTM) | -6.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.10% |
| Nisbah Semasa (MRQ) | 1.23 |
| Aliran Tunai Operasi (OCF TTM) | -33.58 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.95 M |
| Pulangan Atas Aset (ROA TTM) | -52.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -2,951.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Curis, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.2 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -4.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.11 |
|
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.64% |
| % Dimiliki oleh Institusi | 44.65% |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |